MedTrace Logo

Ripretinib in Chinese Patients With Advanced GIST: a Real World Study

NCT05697107 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 308

Last updated 2023-01-25

No results posted yet for this study

Summary

to evaluate the clinical efficacy, safety and predictive factors of ripetinib in Chinese patients with advanced GIST in the real world

Conditions

Interventions

DRUG

Ripretinib Oral Tablet

Oral kinase inhibitor

Sponsors & Collaborators

  • First Affiliated Hospital, Sun Yat-Sen University

    collaborator OTHER

  • Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

    collaborator OTHER

  • Sun Yat-sen University

    collaborator OTHER

  • Fudan University

    collaborator OTHER

  • Xiangya Hospital of Central South University

    collaborator OTHER

  • Fujian Medical University Union Hospital

    collaborator OTHER

  • The First Affiliated Hospital with Nanjing Medical University

    collaborator OTHER

  • First Affiliated Hospital of Zhejiang University

    collaborator OTHER

  • First Affiliated Hospital of Chongqing Medical University

    collaborator OTHER

  • RenJi Hospital

    collaborator OTHER

  • Peking University

    lead OTHER

Principal Investigators

  • Lin Shen, MD · Peking University

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-05-20
Primary Completion
2022-08-30
Completion
2023-12-30

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05697107 on ClinicalTrials.gov